Kerri Fitzgerald

Cancer Nursing Today nonprod

The Janus kinase (JAK) inhibitor ruxolitinib was U.S. Food and Drug Administration-approved for patients with high-risk myelofibrosis (MF) in 2011. Researchers sought to assess the&nbsp;&ldquo;real-world&rdquo; clinical experiences of patients with MF who are treated in the JAK inhibitor era. The results were published in Clinical Lymphoma, Myeloma &amp; Leukemia.Researchers evaluated patterns of care for older patients with MF before and after ruxolitinib approval. They evaluated the Surveillance, Epidemiology, and End Results-Medicare database, and assessed treatment patterns via Medicare Part B and D claims.The study included 528 patients (median age at diagnosis, 76 years) diagnosed with MF between 2007 and 2015. Among 298 patients diagnosed in the ruxolitinib era (defined as 2012-2015), 113 (37.9%) used ruxolitinib. A similar number of users started ruxolitinib at 5, 10, 15, or 20 mg twice a day.Among 31 patients starting at ruxolitinib 5 mg or less twice daily, 48.4% were unable to escalate the dose, and&nbsp;less than 11 users&nbsp;could increase the dose to the maximum 25 mg twice daily dose. Approximately half of ruxolitinib users took hydroxyurea and/or prednisone simultaneously. Median time on ruxolitinib was 11.9 months (interquartile range, 4.2-21.7 months).&ldquo;It would be important to optimize the use of ruxolitinib and develop new drugs that may be administered together with or after ruxolitinib to accomplish better outcomes in older patients with MF,&rdquo; the researchers concluded.

Patterns of Ruxolitinib Use in Older Patients with Myelofibrosis

Myelofibrosis

The Janus kinase (JAK) inhibitor ruxolitinib was U.S. Food and Drug Administration-approved for patients with high-risk myelofibrosis (MF) in 2011. Researchers sought to assess the “real-world” clinical experiences of patients with MF who are treated in the JAK inhibitor era. The results were published in Clinical Lymphoma, Myeloma &amp; Leukemia. Researchers evaluated patterns of care for [...]

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe